Novel Androgen Deprivation Treatment for Advanced Prostate Cancer: Optimizing Benefits, Mitigating Risk

To participate in this activity, please:

Prostate cancer is the most common cancer diagnosed among men in the United States. Considered curable if diagnosed at a localized stage, the survival rate of men with metastatic disease is dramatically reduced. Due to the androgen-dependence of prostate cancer, androgen deprivation therapy (ADT) has been the mainstay and primary therapeutic approach for management of men with metastatic prostate cancer. Join Drs. Robert Dreicer and Michael Cookson as they review the principles of androgen deprivation therapy and discuss the latest clinical data for recently approved ADT agents and studies of ADT-based combination regimens in the treatment of men with metastatic hormone sensitive prostate cancer (mHSPC). The evolving guideline-directed evidence-based approaches for therapeutic intensification in the treatment of mHSPC are also discussed. Listen to the faculty discuss case studies to gain practical insights into choosing optimal therapies that incorporate ADT for individual patients and balance patient preferences with therapeutic goals.

This program is also available as a podcast. You may download it here:

Course Credit:

1.50 AMA PRA Category 1 CreditsTM


Opens: 2021-12-21
Closes: 2022-12-21

Target Audience:

This activity was developed for medical oncologists, nurse practitioners, and other healthcare professionals who care for patients with prostate cancer.

Funding for this Independent Medical Education Grant is being provided from Pfizer Inc and Myovant Sciences Ltd.

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Krithika Subramanian, PhD (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Michael S. Cookson, MD, MMHC

    Professor and Chairman
    Department of Urology
    Donald D. Albers Chair in Urology
    University of Oklahoma Health Sciences Center & Stephenson Cancer Center
    President, Society of Urologic Oncology
    Oklahoma City, Oklahoma

  • Robert Dreicer, MD, MS, MACP

    Deputy Director
    Associate Director for Clinical Research
    University of Virginia Cancer Center
    Co-Director and Section Head of Medical Oncology
    Paul Mellon Urologic Cancer Research Institute
    Professor of Medicine and Urology
    University of Virginia School of Medicine
    Charlottesville, Virginia

Learning Objectives

  • Explain the differences between luteinizing hormone-releasing hormone agonists and gonadotropin-releasing hormone antagonists in terms of mechanism of action and outcomes
  • Select optimal therapy to avoid/reduce cardiovascular risk in patients with advanced prostate cancer
  • Compare and contrast the latest evidence regarding options for patients with advanced prostate cancer
  • Develop treatment strategies incorporating patient-specific factors, including risk factors, concerns, preferences, and adherence information regarding oral vs injectable oncologic therapy

Faculty Disclosures

Michael S. Cookson, MD, MMHC

Advisory Board: Merck, Myovant, Pfizer

Robert Dreicer, MD, MS, MACP

Consultant: Astellas, AstraZeneca, AVEO, Bayer, Eisai, EMD Serono, Exelixis, Gilead, Hinova, Infinity, Janssen, Merck, Myovant, Pfizer, Propella, Seattle Genetics, Tavanta, Veru